慢性卡尔莫杜林-基因酶II激活驱动突变特异性多变性心肌病变的疾病进展
Sarah J Lehman1, Lauren Tal-Grinspan2, Melissa L Lynn3
1Department of Physiological Sciences (S.J.L.), University of Arizona, Tucson.
Circulation
|December 28, 2018
概括
向激活卡尔莫杜林酶II (CaMKII) 显示出对缩性心肌病 (HCM) 治疗的前景. 然而,治疗效应是突变特异性的,需要对个性化干预进行分子层面的理解.
科学领域:
- 心脏病学 心脏病学
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 已知多变性心肌病 (HCM) 的遗传原因,但由于对突变诱导的重塑的不完全理解,有针对性的疗法滞后.
- 在sarcomeric基因中类似的突变可以导致不同的疾病严重程度,强调需要分子层面的洞察力.
- 平衡失调与HCM进展有关,但具体的突变效应尚不清楚.
研究的目的:
- 为了研究早期干预平衡对瘤性HCM的影响.
- 评估卡尔莫杜林酶II (CaMKII) 抑制和diltiazem在HCM小鼠模型中与差异性处理的疗效.
主要方法:
- 使用了两种sarcomeric HCM (心脏热素T R92L和R92W) 的小鼠模型,表现出明显的失调.
- 使用AC3I来抑制CaMKII和diltiazem (L型通道抗剂).
- 评估心脏功能,左心室和心房重塑通过心声学和心房质量,和质网膜Ca2+ATPase活性.
主要成果:
- 在R92W小鼠中,CaMKII抑制改善了透析功能,并减少了心房重塑,与增强的Ca2+ATPase活性相关.
- 在R92L小鼠中,CaMKII抑制恶化了心脏处理,重塑和功能.
- 在R92W小鼠中,diltiazem仅在R92W小鼠中停止了心脏功能障碍的进展,在任何模型中都没有影响心脏重塑.
结论:
- 激活的CaMKII在HCM进展中起着基因突变依赖的作用,这表明它是特定患者队列的精确治疗标.
- 对diltiazem等干预措施的突变特异性反应强调了需要分子层面的理解,以指导HCM中精确的治疗策略.
相关概念视频
Cardiomyopathy III: Hypertrophic Cardiomyopathy
488
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
488
Protein Kinases and Phosphatases
15.1K
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
15.1K
Mutations
94.5K
Overview
94.5K
Cardiomyopathy II: Dilated Cardiomyopathy
566
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
566
Calmodulin-dependent Signaling
6.2K
Calmodulin (CaM) is a calcium-binding protein in eukaryotes that controls various calcium-regulated cellular processes. It has four calcium-binding sites that bind calcium to form the calcium-calmodulin ( Ca2+-CaM) complex. GPCR stimulation increases the calcium levels in the cells that bind to CaM and induces a conformational change.
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
6.2K
Chronic Kidney Disease I: Introduction
728
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
728


